-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Cyclacel Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Cyclacel Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$412K, a 29.7% increase year-over-year.
- Cyclacel Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$2.86M, a 36.5% increase year-over-year.
- Cyclacel Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was -$3M, a 36.5% increase from 2022.
- Cyclacel Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$4.72M, a 26.5% decline from 2021.
- Cyclacel Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was -$3.73M, a 202% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)